Introducing Tremipen®, the portable pen-shaped measuring device that allows objective tremor quantification

Push the power button, get into position and perform the measurement. It’s as simple as that. In a little over 30 seconds, the Tremipen® will display the tremor amplitude (mG) and the tremor frequency (Hz), two parameters commonly used to assess and monitor tremor.

It’s as easy to use as a clinical thermometer

The Measurement Process

Measurement Parameters

Tremor Frequency (Peak Frequency)

The tremor frequency refers to “the speed of shaking”.

Certain diseases may manifest tremors in particular frequency bands (examples are outlined in Table 1). Therefore the frequency of the tremor can give hints about the possible underlying pathological processes.

The tremor frequency is measured in Hz (Hertz). The range of tremor frequencies commonly lie between 3 and 20 Hz.

Tremor Amplitude (Power of Main Peak)

The tremor amplitude refers to how strong and intense a tremor has manifested.

A large-scale study1 determined that the average tremor amplitude of a healthy person is approximately 3 mG.

Tremor amplitude was historically measured in mV (milli-Volt), but in recent years the physically more accurate unit of mG (milli-G) has become more common. 1G is equal to the acceleration or gravity of earth, and the Tremipen® uses an accelerometer to measure the acceleration of the tremor.

1Raethjen, F Pawlas, M Lindemann, R Wenzelburger, G Deuschl, Determinants of physiologic tremor in a large normal population, In Clinical Neurophysiology, Volume 111, Issue 10, 2000, Pages 1825-1837, ISSN 1388-2457,

Table 1. Frequency Ranges of Different Tremor Diseases

Figure adapted from Table 3 in Deuschl, G., Bain, P. and Brin, M. (1998), Consensus Statement of the Movement Disorder Society on Tremor. Mov. Disord., 13: 2–23. doi:10.1002/mds.870131303
All content and property rights belong to the respective authors of the mentioned publication. Tremitas GmbH and Base Medical Pty Ltd do not claim any rights.

Amplitude: Tremipen® vs Tremor Rating Scales

Clinically Proven Objectivity

A clinical trial performed at the Medical University of Graz in 2016 found that the Tremipen® could quantify tremor objectively.

To better understand the relationship between the mG unit and the tremor amplitude, Tremitas has used the data from its own clinical trials to create a correlation guide between the values measured by the Tremipen® and ratings defined in both the “Unified Parkinson’s Disease Rating Scale” (UPDRS) and the “The Essential Tremor Rating Assessment Scale” (TETRAS).

These scales are only for informational purposes and are not to be used as exact scales.

All Benefits at a Glance

Medical Device

In the EU, Tremipen® is a CE-certified medical device of class Im: this guarantees the clinical benefit, accuracy and safety of the device.

Low Weight

The low weight of the Tremipen® guarantees precise measurements. The tremor is not influenced by unnecessary weight.

Precise Technology

Precise sensors and fine-tuned electronic components measure the tremor exactly. And unlike traditional methods, in a portable package.

Easy to Use

A measurement is performed in three simple steps: pushing the button, performing the measurement and reading the results on the display.

Intrinsic Biocompatibility

The case of the Tremipen® is made of an intrinsically biocompatible material that prevents reaction with human skin. By design, Tremipen® doesn’t require prolonged contact to extract meaningful results.

Made in Austria

The Tremipen® has been fully developed and produced in Austria.



Initial Assessment

A new patient arrives at a hospital and complains about tremor in one of their hands. The Tremipen® is used to measure the tremor amplitude and the tremor frequency, which combined with additional tests can provide insight into an initial diagnostic assessment.


Drug Effectiveness

A patient with Parkinson’s disease complains to their doctor that their tremor has worsened. The doctor uses the Tremipen® to take a measurement during the current visit. The doctor prescribes a new medication and asks the patient to return a week later. Another Tremipen® measurement is taken at the next appointment to determine if the new medication has affected tremor intensity.


Home Monitoring

A doctor would like to know how strong a patient is shaking during everyday life. A Tremipen® is lent to the patient and the patient is asked to take measurements at home once a day for a month.


Clinical Trials

A new drug against Essential Tremor will be tested in a clinical trial. The trial participants each receive a Tremipen® and are asked to take measurements twice a day for 2-3 months. On completion of the trial, the Bluetooth interface is used to extract information from the Tremipen® so that measurement data is available for statistical analysis.


Rehabilitation Centres

A rehabilitation centre is focusing on patients with Parkinson’s disease. Nurses follow daily movement protocols to check on patient progress. Tremipen® measurements are added to existing protocols to provide objective parameters for evaluation.


Improvement of Therapy

A doctor would like to try a new therapeutic approach for a patient with tremors, recommending the patient go walking or swimming every day. The doctor takes a Tremipen® measurement before and 2 weeks after the patient beginning the new regimen. Additionally, the patient takes two measurements per day themselves, one before the activity and another upon completion of the activity. The measurements are used to assess progress.

Product Specifications

1 × 1.5 V Battery – Type AAA, Varta


~30g (including battery)

165mm x 18mm (L x Diameter)

Measure tremor frequency (Hz) and tremor amplitude (mG)

Tremor frequency – 3 – 20 Hz
Tremor amplitude – 10 – 1750mG

Tremor frequency – ± 10 % absolute tolerance
or a maximum of ± 2Hz
Tremor amplitude – ± 10% absolute tolerance
or a maximum of ± 100mG